The deal could raise about US$500m–
$1bn. The company is evaluating the pros
and cons of a US or Hong Kong listing and
has not made a decision as yet on the venue.
CloudMinds did not reply to emails from
IFR seeking comment.
Founded in 2015, CloudMinds is a creator,
developer and operator of cloud robots. It
has R&D operations in Santa Clara,
California, Beijing and Tokyo.
Headquartered in the US, CloudMinds was
founded by Chinese entrepreneur Bill
Huang, who was the general manager of the
China Mobile Research Institute, according
to the company’s website.
3OFT"ANKûISûMOREûTHANûAûlNANCIALûINVESTORû
in CloudMinds. In May, SoftBank and
CloudMinds announced they had developed a
new authentication solution by combining
CloudMinds’ blockchain-based authentication
with the mobile carrier’s authentication
platform. This solution will enable mobile
users to log in to websites without having to
enter their user ID and password.
Apart from SoftBank and Foxconn,
Keytone Ventures and Walden International
have also invested in CloudMinds. The
company has recently closed a Series A+
funding of US$147m, said CloudMinds in a
statement in September when it announced
it has extended its collaboration with NYSE-
LISTEDûTELECOMMUNICATIONSûlRMû3PRINTûINû
ARTIlCIALûINTELLIGENCE
FOUR DEALS TO START PRE-MARKETINGFour companies are set to start pre-
marketing this week for Hong Kong IPOs of
a combined US$2.7bn, if they win listing
approvals from the Stock Exchange of Hong
Kong.
Chinese online travel service provider
TONGCHENG-ELONG plans to raise up to
53MnBNûFROMûITSûmOAT
CMB International, JP Morgan and Morgan
Stanley are the joint sponsors.
Tongcheng merged with eLong in March
this year. The company is backed by tech
giant Tencent Holdings and travel service
provider Ctrip, which own respective stakes
of 24.92% and 22.88%.
/NLINEûPARENTINGûlRMûBABYTREE GROUP,
backed by e-commerce giant Alibaba Group,
intends to raise up to US$800m from an IPO.
Babytree, which also counts
conglomerate Fosun International among
its backers, is China’s largest maternity and
child-focused online community and had
139m monthly active users last year.
Alibaba in late May invested US$214m in
"ABYTREE ûVALUINGûTHEû
YEAR
OLDûlRMûATû
Rmb14bn (US$2bn).
China Merchants Securities, Haitong
International and Morgan Stanley are joint
sponsors for the IPO.
Mobile advertising provider WANKA ONLINE,
plans to raise US$400m–$500m.
The company marketed more than 2,800
mobile apps in 2017 and recently expanded
into the online game co-publishing and
online video distribution businesses,
ACCORDINGûTOûREGULATORYûlLINGS
CICC, Citigroup, ICBC International and
Macquarie are joint sponsors on the proposed
mOAT
Mobile marketing company MOBVISTA aims
for a US$300m–$400m listing.
CMB International and UBS are the joint
sponsors.
-OBVISTAûPOSTEDûNETûPROlTûOFû53MûINû
2017, up 38% from a year earlier. Its
revenues in 2017 were US$313m.HAIER COMPLETES FIRST D-SHARE IPOShanghai-listed QINGDAO HAIER has completed
THEûlRSTû$
SHAREû)0/ûINû&RANKFURTûAFTERû
pricing the deal near the bottom of an
indicative price range of €1.00–€1.50.
The company sold 265m D-shares at €1.05
each to raise €278.3m (US$320m). There is a
greenshoe of 15%, or 39.75m D-shares.
Trading began on Wednesday, with the
stock opening slightly above pricing at €1.06
BUTûCLOSINGûmATûATûõûANDûREMAININGûATû
that level on both Thursday and Friday.
Three cornerstone investors took up a
COMBINEDûõMûOFûTHEûmOATû3ILKû2OADû
Fund has committed to purchase 55m
shares, while Camry Investment and Rechi
Precision have backed €60m and €20m,
respectively.
Haier’s Frankfurt listing introduces a new
class of equities for Chinese companies.
D-shares, similar to Hong Kong-listed
H-shares, are new instruments being touted
by the China Europe International
Exchange.
Deutsche Bank was sole global coordinator,
and joint bookrunner with CICC, JP Morgan
and UBS.QINGDAO HAIER BIOMEDICAL FILES IPOQINGDAO HAIER BIOMEDICAL, the medical device
UNITûOFû(AIERû#ORPORATION ûHASûlLEDûFORûANû
IPO with the Stock Exchange of Hong Kong.
It is unclear how much the company is
looking to raise, but a banker who has
pitched for the transaction said the deal
might be around US$100m–$200m.
Founded in 2005, the company designs,
manufactures and markets laboratory
equipment for commercial use. Its signature
product, a biomedical refrigerator, is
DESIGNEDûTOûENABLEûSCIENTIlCûRESEARCHERSûTOû
keep vaccines, blood samples and related
life-science specimens to perform research
projects and to produce pharmaceutical
products.Haier Biomedical is 40% held by a
lNANCIALûHOLDINGûPLATFORMûOFû(AIERû
Corporation, 30% by US private equity
company Carlyle and 8% by healthcare
INVESTMENTûlRMû6IVOû'ROUP
It is also 22% owned by Shanghai-listed
Qingdao Haier.
Haier Biomedical posted a half-year
PROlTûOFû2MBMû53M ûFORûTHEûPERIODû
ended June 30, down from Rmb69m a year
EARLIERû)TûHADûFULL
YEARûPROlTSûOFû2MBMû
in 2017 and Rmb122m in 2016.
ABC International is the sole sponsor of
THEûmOATINNOVENT PRICES IPO NEAR TOP
OF RANGEBiopharmaceutical company INNOVENT
BIOLOGICS has raised HK$3.3bn (US$421m)
from its Hong Kong IPO after pricing it
near the top of the indicative price range.
The company sold 236m primary shares,
or 21% of the enlarged share capital, at
HK$13.98, versus the HK$12.50–$14.00
range.
4HEûlNALûPRICEûVALUESûTHEûCOMPANYû
at about US$2bn. There is a 15%
greenshoe.
Despite the weaknesses of other biotech
IPOs and recent volatile market conditions,
Innovent drew strong demand for the
mOATû4HEûBOOKS ûEXCLUDINGûTHEû
cornerstone tranche, were more than 10
times covered, said people involved.
Innovent secured 10 cornerstone
investors for a total of US$245m.
The shares are due to list on October 31.
China Merchants Securities, Goldman Sachs,
JP Morgan and Morgan Stanley are joint
sponsors for the IPO.TWO BIOTECHS PLAN IPOTwo biotech companies, ALPHAMAB and
ZESHENG TECHNOLOGY, are planning to list in
Hong Kong in 2019.
Alphamab has started working with
BANKSûONûAûmOATûTHATûCOULDûRAISEûABOUTû
US$200m, according to people close to the
deal.
Established in 2009, it has a pipeline of
more than 20 biologics programmes in
oncology and several other areas.
Meanwhile, the board of Zesheng
Technology has approved a plan to list in
Hong Kong. The company is already listed
on National Equities Exchange and
Quotations, China’s third board, an over-
the-counter market.
It plans to sell 78m shares, or up to 30%
of its enlarged share capital, according to
an announcement. A total of 89.7m shares
will be sold if a 15% greenshoe is fully
exercised.